Actively Recruiting
Evaluation of the Use of Granulocyte Colony Stimulating Factor (GCSF) in Post Kasai Type 3 Biliary Atresia
Led by National Liver Institute, Egypt · Updated on 2024-12-11
40
Participants Needed
1
Research Sites
99 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The aim of the study is to evaluate the use of Granulocyte Colony Stimulating Factor (GCSF) on the clinical and biochemical outcome of type 3 biliary atresia post kasai.
CONDITIONS
Official Title
Evaluation of the Use of Granulocyte Colony Stimulating Factor (GCSF) in Post Kasai Type 3 Biliary Atresia
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Infant diagnosed with biliary atresia and biliary atresia score greater than 23.927
- Undergoing Kasai porto-enterostomy with confirmed type 3 biliary atresia anatomy during surgery
- Age between 18 days and 1 year
You will not qualify if you...
- Presence of major cardiac, renal, pulmonary, or neurological malformations or illnesses
- Diagnosis of hemoglobinopathies such as sickle cell anemia
- Active systemic infection at time of screening
- White blood cell count greater than 20,000 cells/mm3
- Platelet count less than 40,000 cells/mm3 or greater than or equal to 800,000 cells/mm3
- History of purpura fulminans or unexplained blood clotting conditions
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
National Liver Institute
Cairo, Menofia Governorate, Egypt, 32511
Actively Recruiting
Research Team
M
Marwa Narwa Foad Asker, master
CONTACT
B
Behairy Behairy El Sayed Behairy, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here